Call 1-888-805-4555
for 24/7 on-call assistance
This information is provided for educational purposes only. Bristol Myers Squibb cannot guarantee insurance coverage or reimbursement. Coverage and reimbursement may vary significantly by payer, plan, patient, and setting of care and is subject to frequent change. It is the sole responsibility of the healthcare provider to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient.
Coverage and reimbursement for Bristol Myers Squibb CAR T cell therapies may vary based on payer-specific requirements, potential site/setting of care, and patient-specific benefits.
Benefit verification (BV) with a patient’s payer is critical to help identify specific considerations for each appropriate patient for Bristol Myers Squibb CAR T cell therapies. Our Insurance Coverage Look-up tool can provide information to assist in the BV process, or Cell Therapy 360® can provide BV assistance.
Download the CAR T cell therapy BV checklist for a helpful guide on the type of information that needs to be confirmed during the BV process for CAR T cell therapy treatment.
Treatment centers should confirm access prior to apheresis scheduling, including BV, prior authorization (PA) approval, and single case agreement (if required).
For questions, please contact your Bristol Myers Squibb Account Representative or call Cell Therapy 360 at 1-888-805-4555.
CAR T cell therapies are covered by Medicare FFS for FDA-approved use(s) per the National Coverage Determination (NCD), according to which, healthcare facilities administering CAR T cell therapy must be certified by the respective manufacturer under the applicable Risk Evaluation and Mitigation Strategy (REMS) program.1
Under the NCD, consistent coverage conditions for CAR T cell therapies apply to all A/B Medicare Administrative Contractor (MAC) jurisdictions.1
NCD flashcardCAR T cell therapy treatment-related out-of-pocket (OOP) costs for Medicare FFS patients may vary based on:
For Medicare FFS patients without secondary or supplemental insurance, out-of-pocket costs are typically capped per service in the hospital outpatient setting, at the level of the inpatient deductible (up to $1,556 in 2022).2*
*Full Part B 20% coinsurance applies when outpatient services are provided in an Outpatient Prospective Payment System (OPPS)–exempt hospital or an outpatient clinic/physician office.
Visit the Resource Library for informative downloadable tools.
Although MA plans may issue their own medical policies and PA requirements for FDA-approved CAR T cell therapies, coverage for MA patients must be consistent with the NCD.3,4 Specific PA requirements may vary among MA plans.
Patient benefits may vary among MA plans:
For MA patients, OOP costs for Part A and B services are subject to an annual maximum (on average, up to $5,091 for in‑network services in 2021).5†
*Site/setting-of-care decisions are at the sole discretion of the treating physician.
†Federal regulations require MA plans to have a limit on annual patient OOP costs for Part A and B services, which are not to exceed $7,550 (in-network) or $11,300 (in-network and out-of-network) in 2021.5
Visit the Resource Library for informative downloadable tools.
CAR T cell therapies are generally covered by commercial plans, typically with detailed PA requirements that are consistent with the FDA-approved labeling.
Specific PA requirements may vary among commercial plans.
Click here for product-specific PA submission tip sheet.
Patient benefits may vary among commercial plans, including:
OOP costs for most commercial patients are subject to an annual maximum (on average, up to $4,272 for in-network services in 2021).5
Visit the Resource Library for informative downloadable tools.
For product-specific resources, click here.
CAR=chimeric antigen receptor.
This information is provided for educational purposes only. Bristol Myers Squibb cannot guarantee insurance coverage or reimbursement. Coverage and reimbursement may vary significantly by payer, plan, patient, and setting of care and is subject to frequent change. It is the sole responsibility of the healthcare provider to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient.
You are now entering the Cell Therapy 360® Scheduling and Apheresis Portal.
You are about to leave this Bristol-Myers Squibb Company site. You are being redirected to another Bristol-Myers Squibb Company site.
You are now leaving this Bristol Myers Squibb site.
This internet site may provide links or references to other sites. BMS has no responsibility for the content of such other sites and is not liable for any damages or injury arising from that content. Any links to other sites are provided merely as a convenience to the users of this internet site.
Are you sure you want to leave the enrollment section?
Your work will not be saved until you fill out the Patient Authorization and Consent page and submit your part of the enrollment form.
It won’t take long!
You are about to leave this Bristol-Myers Squibb Company site. You are being redirected to another Bristol-Myers Squibb Company site.
Please confirm your patient’s diagnosis:
Please confirm that you are a:
You are about to leave this Bristol-Myers Squibb Company site. You are being redirected to another Bristol-Myers Squibb Company site.
Select a disease state:
R/R=relapsed/refractory.
You are about to leave this Bristol-Myers Squibb Company site. You are being redirected to another Bristol-Myers Squibb Company site.
Insurance coverage information is currently available for R/R large B-cell lymphoma only.
R/R=relapsed/refractory.
You are about to leave this Bristol-Myers Squibb Company site. You are being redirected to another Bristol-Myers Squibb Company site.
Please confirm your patient’s diagnosis:
R/R=relapsed/refractory.